NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Pharvaris N.V. (PHVS) Stock Analysis

Pharvaris N.V. (PHVS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PHVS

$30.66

−$0.24 (−0.78%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PHVS with… →

PHVS Key Statistics

As of Oct 21, 2026
Trading
Open
$31.22
Previous Close
$30.90
Day's Range
30.55–31.50
52-Week Range
21.02–43.25
Volume
393.54K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−2.46
Valuation
Market Cap
$2.15B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.06
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$175.70M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
70.20M
1-Year Return
+27.80%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
771.38K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PHVS closed at $30.66, +27.80% over 1 year.

Pharvaris N.V. (PHVS) has a market capitalization of $2.15B.

In fiscal 2025, PHVS reported revenue of $0.00.

PHVS Stock Return by Calendar Year

Pharvaris N.V. (PHVS) return since Feb 2021: what $10,000 became

1 year
$10,000 $12,780
+27.80%
5 years
$10,000 $20,716
+107.16%
Since Feb 2021
$10,000 $10,572
+5.72%

If you had invested $10,000 in Pharvaris N.V. (PHVS) at the close on February 5, 2021, the earliest close on record here, it would have been worth $10,572 at the close on October 21, 2026: +5.72% in total, +0.98% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+10.49%
2025+44.76%
2024−31.66%
2023+149.33%
2022−21.82%
2021 (partial year)−50.38%

As of October 21, 2026.

PHVS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$175.70M—
2024$0.00−$134.22M—
2023$0.00−$100.88M—
2022$0.00−$76.33M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$169.82M−$175.70M—
2024$0.00—−$145.69M−$134.22M—
2023$0.00—−$96.91M−$100.88M—
2022$0.00—−$86.71M−$76.33M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Pharvaris N.V. (PHVS) carries a market capitalisation of $2.15B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 148 employees.

The 52-week range on file runs from $21.02 to $43.25. The most recent close on file for PHVS is $30.66, dated October 21, 2026. That is −$0.24 (−0.78%) against the previous close. The latest close sits 45.86% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $175.70M. Trailing earnings per share are −3.06.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the total return is +27.80%. Measured over 5 years, that is +15.68% a year compounded. The reported beta is −2.46. Daily returns over the trailing 5 years annualize to a volatility of 177.18%.

Growth & Income

No dividend is on file for PHVS.

Across the complete calendar years on file, 2023 returned +149.33% and 2024 returned −31.66%. Of the 4 complete calendar years on file, 2 finished higher. So far in 2026 the total return is +10.49%.

Peer Comparison

Pharvaris N.V. (PHVS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Pharvaris N.V. PHVS $2.15B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Pharvaris N.V. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Pharvaris N.V.

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Visit website →